Phase II/III trial to assess LAG-3 immunotherapy in breast cancer
Drug Discovery World
MARCH 24, 2023
Efti As a first-in-class soluble LAG-3 protein targeting MHC Class II ligands on antigen-presenting cells (APC), efti is positioned to improve clinical outcomes from standard-of-care chemotherapy. Its activation of APCs (e.g., month median overall survival (mOS) improvement, statistically significant mOS improvements between 4.2
Let's personalize your content